Photo by museumsvictoria from unsplash
The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and… Click to show full abstract
The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.
Keywords:
public biotech;
2016 numbers;
biotech 2016;
biotech
Journal Title: Nature Biotechnology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Biotechnology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!